Chris Garabedian, the chief executive who turned Cambridge, Mass.-based Sarepta Therapeutics from a floundering antiviral company called AVI Biopharma into an investor darling, resigned today, according to a press release from the company. Garabedian’s relationships with both investors and, more problematically, the Food and Drug Administration had become tense as [...]